Fig. 1.

Study design and mutation rates of key genes in fifty-two muscle-invasive bladder cancer patients. a. Fifty-two patients were split into responders and nonresponders based on their pathologic response to neoadjuvant chemotherapy. TURBT, transurethral resection of bladder tumor. b. The alteration landscape of the aggregate cohort (n = 52 patients) are displayed in the center. Each column represents a tumor, and each row represents a gene. TERT, FGFR3, TP53, PIK3CA, ERBB2 and TSC1 are listed on the left and the center panel is divided into responders (left and green) and nonresponders (right and orange). The mutation rates (top) and mutational frequency (left) are also summarized.